The FDA on July 28 approved RiVive, 3 mg naloxone hydrochloride nasal spray for over-the-counter, nonprescription use for the emergency treatment of known or suspected opioid overdose. With drug overdose persisting as a major public health issue in the United States, approval of this nonprescription product helps increase consumer access to naloxone. As part of the FDA’s Overdose Prevention Framework, the agency continues to take actionable steps to increase availability and expand access to overdose reversal products.
More information is available at FDA.gov.
